Professional Documents
Culture Documents
Economic Data
New home sales for May rose 2.9% to 610K annual rate, above consensus for 590K; previous
three months new home sales data revised up 34K; said median new home price rose 16.8% YoY
to $345,800 while 18% of new homes sold in May cost more than $500,000, up from 14% last
month; months supply at 5.3 in May compared to 5.3 in April
The "flash" reading of manufacturing purchasing managers (PMI) index fell to a nine-month
low in June. The IHS Markit manufacturing index fell to a reading of 52.1 in June from 52.7 in
May. The flash services PMI slowed to a 3-month low of 53 from 53.6 in May. The flash readings
are based on 85% to 90% of responses.
Commodities
Oil prices advanced 27c to settle at $43.01 per barrel, but both Brent and WTI posted their 5th
consecutive weekly decline after slipping into bear market this week. Both prices have dropped
over 20% from January highs on global oversupply fears, though inventory data this week for
crude was fairly bullish (though distillates and gasoline stockpiles have grown). For the week, WTI
crude slipped more than 4% to lowest level since August.
Gold prices ended higher by $7.00, or 0.6% to settle at $1,256.40 an ounce Friday, posting a gain
for a third session in a row, as prices recovered from 5-week lows on Tuesday. Prices for the
precious metal settled a dime below their finish a week ago, getting a lift late week as the dollar
declined on mixed data.
Energy
Baker Hughes (BHI) weekly rig count data showed the total rig count rose 8 to 941, oil rigs up 11
to 758 (23rd straight week of gains) and gas rigs fell -3 to 183; overall though, energy stocks with a
nice rebound on the day after several days of selling pressure with WTI falling to 10-month lows.
Many research analysts threw in the towel this week, with at least four firms cutting ratings on
several E&P related names and lowering WTI and Brent forecasts. Teekay family of stocks (TK,
TNK, TOO) bounced off 52-week lows on day.
Financials
Stress tests: as expected, Fed stress tests results under Dodd-Frank Act (DFAST) showed all 34
banks exceed minimum projected capital and leverage ratios under severely adverse scenarios,
while changes in portfolio composition and risk characteristics have contributed to lower loss
rates in 2017 compared to last years DFAST. Next up, the Fed releases Comprehensive Capital
Analysis and Review (CCAR) results on June 28, 4:30pm (last night). MS and STT skated closer to
the required minimums than expected according to Barclays
Other banking news; Germanys Commerzbank is close to reaching a deal with workers
representatives that will lower the expected costs of its major restructuring plan, but it will push
it to a loss for the second quarter
REITs; FOR gets improved revised offer from DHI of $17.75 per share, up from prior bid of $16.25
in cash (Starwood recently raised its bid to $16 from $15.50 on FOR https://goo.gl/YjxP2d; Bank
America with a few rating changes as it upgraded PLD to buy and downgraded DRE in the
industrial REIT sector; in mall REITs, SKT downgraded at Bank America to underperform, while
BTIG defended group (reit buys on SPG, MAC, GGP); BTIG also defended Strip Center shares
which are down an average of 7% since last Fridays announcement of AMZN/WFM (reiterates
buys on KIM, KRG and ROIC); Jefferies out with a Franchise Note looking at the impact of e-
commerce warehouse demand on the Industrial REITs saying E-com retailers need 3x as much
warehouse space as traditional retailers and we believe E-com growth will add 50bps/year of
growth to warehouse demand says prefers REXR and STAG
Healthcare
Large Cap Pharma; small giveback in names like BMY after strong week of gains; OCUL weak after
being downgraded to equal-weight at Morgan Stanley saying recent management changes add to
continued uncertainties (CEO transition and CFO exit); CARA said the FDA gave I.V. CR845
breakthrough therapy designation as a treatment of moderate-to-severe uremic pruritus in
chronic kidney disease patients undergoing hemodialysis; MDT authorizes $5B stock buyback and
raises dividend to 46c from 43c; the NDA for PTLAs betrixaban has been approved by FDA
Senate healthcare bill: analyst feedback positive for some sectors: Leerink said they see the draft
version of the Senate bill as better than expected and driving the outperformance particularly in
our Facilities coverage and also for our Managed Care names (all of which were up yesterday
AET, CI, UNH, HUM in managed care at 52-week highs along with hospitals THC, CYH, UHS. Said
specifically, stabilization of the Exchanges through substantial funding toward reinsurance, and
risk stabilization is a direct positive for the health insurance stocks and indirectly for the Facilities
names that have enjoyed reduction in Bad Debt from coverage expansion.
Biotech movers; what a week for biotech (IBB), on track for a 10% gain led by cancer related
drugs on better trials, expectations the Trump administration executive order will focus on easing
regulation for companies, rather than limiting prices as initially feared; AVEO shares rise after its
cancer drug tivozanib was recommended for approval in Europe; REGN slips after its Dupixent
prescription growth showing signs of deceleration, according to one analyst (shares had touched
52-week highs yesterday); BLUE shares slipped after reporting mixed data on its treatment of
beta-thalassemia, where 1 out of 3 patients had a weaker response to the therapy
Want a free trial to The Hammerstone Report 4x Daily ? Sign-up for a trial today at
www.thehammerstonereport.com
Please be sure to check out The Hammerstone Institutional Feed for News and Analysis for the
Informed Trader at www.hammerstoneinstitutional.com
***DISCLAIMER/LIMITATION OF LIABILITY: Hammerstone Inc. (the Report) provides information and data and does NOT provide any individual investment advice or money management
assistance and does NOT attempt to influence the sale or purchase of securities. The Report is intended for informational purposes only and does not claim to be actionable for investment
decisions. The information contained in the Report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. The
Report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. The Report is prepared for
general information purposes only and does not consider the specific investment objectives, financial situation, and particular needs of any individual subscriber, person, or entity